TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06385821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grippol Quadrivalent
Description: Solution for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Grippol Plus
Description: Suspension for intramuscular and subcutaneous administration, 0.5 ml/dose. Children from 36 months to 5 years - in the upper third of the outer surface of the shoulder intramuscularly (in the deltoid muscle) at a dose of 0.5 ml once (Day 1). Children from 6 to 35 months - in the anterolateral surface of the thigh intramuscularly, 0.25 ml twice with an interval of 3-4 weeks (Day 1, Day 25±3).
Study: NCT06499935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rigid Taping
Description: It is usually light brown or beige and is designed to hold firm, making it ideal for providing support or stability to a joint.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio-Taping
Description: Kinesio Taping Method is a therapeutic tool utilised by rehabilitation specialists in all programs. Kinesio Taping Method utilises four types of Kinesio Tex Tapes, each with specific properties designed for use on fragile, sensitive skin or applied with higher tensions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Taping
Description: Sham taping is the use of any type of tape in a random and ineffective fashion for the purposes of comparison with other taping techniques and types.
Study: NCT06047249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KAP Popular Science Research
Description: By conducting a survey questionnaire, investigate the knowledge, attitude, and practice tendencies of patients and their caregivers towards a certain disease, and conduct relevant science popularization；Pre discharge satisfaction survey questionnaire

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No KAP Popular Science Research
Description: Pre discharge satisfaction survey questionnaire
Study: NCT06471738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: BTK inhibitor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal antibody to CD20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: BCL-2 inhibitor
Study: NCT06298643

Intervention type: PROCEDURE
Intervention: Red blood cell transfusion
Description: ≥2 units of red blood cell transfusion

Intervention type: PROCEDURE
Intervention: Red blood cell transfusion
Description: 0 units or \<2 units of red blood cell transfusion
Study: NCT06571279

Intervention type: OTHER
Group type: OTHER
Intervention: Plant-based diet
Description: Participants will follow one week Western diet run-in where participants will consume a diet high in processed foods (e.g., fast food, chips, soda). Following the run-in phase, participants will consume plant-based meals and snacks for 5 weeks, which will be delivered directly to their homes or provided directly by the study team. Participants will be permitted to consume one cheat meal of up to 500kcal per week, which will all be reported to the study team.
Study: NCT06314698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narlumosbart
Description: Administered by subcutaneous injection once every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Administered by subcutaneous injection once every 4 weeks.
Study: NCT06571214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®)
Description: As a r-hFSH agent, Gonal-f® is used for COS. It is a prefilled ready to use pen device containing follitropin alfa for injection and is designed for subcutaneous self-administration by patients undergoing COS for ART. It is available as dose presentations of 150 IU and 450 IU. The investigators and/or his/her delegate/s will explain the use of Gonal-f® prefilled pen. Gonal-f® will be prescribed by the investigator based on clinical diagnosis and treatment routines, and will not be provided free of charge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)
Description: This product is a white freeze-dried powder and a colorless and clear injection solvent, and stored away from light under 25℃ in the original packaging. Luveris® will be provided free of charge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)
Description: This product is a white freeze-dried powder and a colorless and clear injection solvent, and stored away from light under 25℃ in the original packaging. Luveris® will be provided free of charge.
Study: NCT05750693

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PIK3CA analysis
Description: PIK3CA will be investigated together with HER2 in pre-NAD tissue samples, in order to evaluate the correlation with response to NAD chemotherapy, with a 16-gene MYRIAPOD kit. This evaluation will be performed on all 58 patients in the study for group (responders and not responders).~Moreover 10 patient samples (5 responders and 5 non-responders) will be subjected to gene expression profile analysis. Specifically, a transcriptomic analysis will be performed on total RNA from one inch of cells (10-50 cells isolated by LCM from FFPE biopsy, RNA seq) which will allow to have the transcriptional profile for each patient of protein-coding transcripts (coding RNAs) and long non-coding RNAs.~In addition, an NGS analysis by TSO500 will be performed in parallel, on the slide following the previous one, to have the genome sequence (523 genes) on the same 10-50 cells isolated by LCM from FFPE biopsy for the identification of any mutations.
Study: NCT05841810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Outreach
Description: Community outreach using mHealth messaging will be led by community weavers via SMS and voice messages about COVID-19 vaccines and preventive care engagement in languages spoken by patients (i.e., Spanish, Arabic, Vietnamese).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Outreach
Description: Community outreach using mHealth messaging will be led by community weavers via SMS and voice messages about COVID-19 vaccines and preventive care engagement in languages spoken by patients (i.e., Spanish, Arabic, Vietnamese).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Outreach
Description: Community outreach using mHealth messaging will be led by community weavers via SMS and voice messages about COVID-19 vaccines and preventive care engagement in languages spoken by patients (i.e., Spanish, Arabic, Vietnamese).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Coordination
Description: Inclusive of standard of care coordination with added focus on completing outstanding preventive care practices. Care coordination will be focused on collaborative problem-solving and case management to help patients schedule and attend recommended annual preventive health care, including a routine physical exam, recommended preventive screenings and COVID-19 vaccination
Study: NCT03160430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apabetalone
Description: RVX000222 oral (apabetalone), 100 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: apabetalone
Description: RVX000222 oral (apabetalone), 100 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: apabetalone
Description: RVX000222 oral (apabetalone), 100 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: matching placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: matching placebo capsule
Study: NCT06061458

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: speech auditory brainstem response
Description: A diagnostic objective test to evaluate the speech process in hearing impaired children

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: speech auditory brainstem response
Description: A diagnostic objective test to evaluate the speech process in hearing impaired children

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: speech auditory brainstem response
Description: A diagnostic objective test to evaluate the speech process in hearing impaired children
Study: NCT06113042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health talks, learning packs
Description: All participants can join the health talks and receive the learning packs.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health talks, learning packs
Description: All participants can join the health talks and receive the learning packs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health talks, learning packs
Description: All participants can join the health talks and receive the learning packs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health talks, learning packs
Description: All participants can join the health talks and receive the learning packs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification programme
Description: In Group 1: The programme includes both knowledge and activity/practicum sessions for children and parents. It will be carried out in district community hubs.~Group 2: The programme focuses on the knowledge sessions for parents. It will be carried out in schools.~Group 3: The programme focuses on the activity/practicum sessions for children and parents. It will be carried out in district community hubs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification programme
Description: In Group 1: The programme includes both knowledge and activity/practicum sessions for children and parents. It will be carried out in district community hubs.~Group 2: The programme focuses on the knowledge sessions for parents. It will be carried out in schools.~Group 3: The programme focuses on the activity/practicum sessions for children and parents. It will be carried out in district community hubs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification programme
Description: In Group 1: The programme includes both knowledge and activity/practicum sessions for children and parents. It will be carried out in district community hubs.~Group 2: The programme focuses on the knowledge sessions for parents. It will be carried out in schools.~Group 3: The programme focuses on the activity/practicum sessions for children and parents. It will be carried out in district community hubs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School healthy environment evaluation
Description: Evaluation on school healthy environment will be carried out in Group 1 and Group 2 to enhance the schools to provide a healthy school environment to children.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School healthy environment evaluation
Description: Evaluation on school healthy environment will be carried out in Group 1 and Group 2 to enhance the schools to provide a healthy school environment to children.
Study: NCT05294263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline is a selective nACHr partial agonist of the 4 2 subtype and a full agonist of the 7 subtype

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching, inactive medication
Study: NCT04979221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Description: Cyproheptadine 8mg three times a day during 10 days
Study: NCT05864027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led Oral Health Recovery Group
Description: The interactive Oral Health Recovery group will be centered around the tailored materials previously developed, with topics such as it's never too late to make a change, oral health and whole health, taking care of your teeth, and going to the dentist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Video about Oral Health
Description: The video comparison will be pulled from Toothflix 2.0 Patient Education DVD Series, which are patient education videos developed by the American Dental Association.
Study: NCT05305365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBS72S
Description: QBS72S 18mg/m2 injection given intravenous once a month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBS72S
Description: QBS72S 18mg/m2 injection given intravenous once a month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBS72S
Description: QBS72S 18mg/m2 injection given intravenous once a month.
Study: NCT04349852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BrainHQ Cognitive Training Modules
Description: The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The subtests exercises include 6 modules for the experimental group: 1) Sound Sweeps: which is identify whether sound pitches are going up or down; 2) Memory Grids: matching pairs of words; 3) Syllable Stack: recognition of sequences of confusable syllables; 4) Fine Tuning: recognition of the order of confusable syllables; 5) To-Do List Training: reconstruction of sequences of verbal instructions; 6) In The Know: identification of details in a verbally presented story. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BrainHQ People Skills Modules
Description: The BrainHQ is a computerized training program developed from Posit Science designed to improve multiple cognitive domains. The BrainHQ will provide 3 training modules for the control group: 1) Recognition: a picture of a face is presented briefly and then the subject picks the recognized face from 3 pictures. 2) Face to Face: matching the emotional expression of 3 pictures to the emotional expression of the picture previously presented; 3) Face Facts: recalling 3 facts about a person that was previously presented. Participants will spend 45 minutes at each training session. Since the intervention is presented both visually and verbally through the computer, participants will be asked to complete their training in a quiet space and time to complete these activities.
Study: NCT06323304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: Auricular acupressure therapy will be performed once a week for 4 weeks using Vaccaria seeds, which is an herb in traditional medicine. The acupoints on the ear that will be treated with auricular acupressure therapy are Shenmen (TF4), Internal nose (TG4), Lung (CO14), Wind stream (SF1,2i), Adrenal gland (TG2p). These acupoints are believed to be effective in the treatment of allergic rhinitis. The patches will be kept on the auricle for one week.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupressure
Description: Sham acupressure therapy will be performed once a week for 4 weeks using Vaccaria seeds. The acupoints that will be treated with auricular acupressure therapy are Helix 2 (HX10), Shoulder (SF4), Clavicle (SF6), Anus (HX5) and Tooth (LO1). These acupoints are not used to treat allergic immune-related problems or respiratory diseases. The patches will be kept on the auricle for one week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of fluticasone propionate nasal spray as needed, and lifestyle modifications.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment, continuously administered over the 4-week intervention period, involves standard doses of fluticasone propionate nasal spray as needed, and lifestyle modifications.
Study: NCT04847050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Messenger ribonucleic acid (mRNA)-1273 Vaccine
Description: A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 and 29 for vaccine naive cohorts.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Messenger ribonucleic acid (mRNA)-1273 Vaccine
Description: A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 and 29 for vaccine naive cohorts.
Study: NCT06157294

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular pulsed radiofrequency
Description: Intra-articular pulsed radiofrequency procedures for the treatment of facet joint-related low back pain are performed under sterile conditions in the operating room. The application is performed under fluoroscopy guidance using a 20 gauge 10 mm active tip radiofrequency needle. When the intra-articular joint, which is the target tissue, is reached with the help of fluoroscopy images, pulse radiofrequency treatment will be applied with the parameters being maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Median branch pulsed radiofrequency
Description: Median branch pulsed radiofrequency procedures for the treatment of facet joint-related low back pain are performed under sterile conditions in the operating room. The application is performed under fluoroscopy guidance using a 20 gauge 10 mm active tip radiofrequency needle. When the median branch region, which is the target area, is reached with the help of fluoroscopy images, location confirmation will be provided by giving sensory and motor stimulation. Pulse radiofrequency treatment will be applied with the parameters being maximum temperature 42 degrees, 45 volts, duration 6 minutes, pulse rate 2 hertz and pulse width 20 milliseconds.
Study: NCT04847050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster
Description: A rapid response, proprietary messenger RNA (mRNA)-based vaccine platform. 100 mcg administered intramuscular (IM) on Day 1 for vaccine booster cohorts. Participants may receive up to 3 booster injections on study.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: Baseline (-28 days/Day 1); and Day 29 (+/- 3 days).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: Baseline (-28 days/Day 1); and Day 29 (+/- 3 days).
Study: NCT05283200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga instructor will teach gentle yoga focused on meditation, breathing exercises, and mindfulness techniques to promote well-being and stress reduction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Psychologist will provide patients with psycho-educational and behavioral health strategies to promote seizure prevention and stress management skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Music therapist will teach a variety of ways that participants might incorporate music into their daily lives as a means of self-expression, coping, and stress reduction.
Study: NCT05010499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: femoral nerve block receives 20 ml of levobupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Fascia iliaca block receives 40 ml of levobupivacaine 0.25%
Study: NCT06219174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV Q3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg IV Q3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine
Description: Dose Level -1: 4500 mg/m2 by mouth (PO) daily Dose Level 1: 6750 mg/m2 by mouth (PO) daily Dose Level 2: 9000 mg/m2 by mouth (PO) daily
Study: NCT04847050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Use of prophylactic antibiotics is recommended according to institutional standards.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: Use of prophylactic antibiotics is recommended according to institutional standards.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-viral agents
Description: Use of prophylactic antiviral agents is recommended according to institutional standards.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-viral agents
Description: Use of prophylactic antiviral agents is recommended according to institutional standards.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-fungal agent
Description: Use of prophylactic antifungal agents is recommended according to institutional standards.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-fungal agent
Description: Use of prophylactic antifungal agents is recommended according to institutional standards.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-emetics
Description: Use of prophylactic anti-emetics is recommended according to institutional standards.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anti-emetics
Description: Use of prophylactic anti-emetics is recommended according to institutional standards.
Study: NCT05305313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.